Piccadily Sugar (507498)
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹35.71 |
| Market Cap | ₹83.03 Cr |
| P/E Ratio | 44.4 |
| ROCE | -13.66% |
| ROE | 17.07% |
| Dividend Yield | 0% |
| Profit Growth | 112.26% |
| Debt/Equity | — |
| Sales Growth | -37.21% |
| Sector | Agricultural Food & other Products |
| Book Value | ₹4.6 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
This looks less like a compounder and more like a cyclical commodity situation. I start with sales: they are down 37.21%. A business cannot create durable value when revenue is collapsing at this pace. The reported profit growth of 112.26% sounds attractive, but with a P/E of 44.40 and latest quarter sales of just ₹1 Cr and net profit ₹0 Cr, the current earnings power is razor-thin. Sugar is a commodity, so I have no pricing power, no customer franchise, and no moat to protect returns. Mr Market is putting an ₹83 Cr market cap on a company with book value of ₹4.60 per share. That means I am paying 7.76 times book for a firm whose ROCE is -13.66%. Negative ROCE tells me operations are not covering the capital employed, though the 17.07% ROE is positive. There is no dividend, so the minority shareholder does not get paid while waiting. The Piotroski score of 5/9 suggests some signs of life, but not evidence of quality. The PEG ratio of 0.40 is misleading because commodity profits are cyclical and often mean revert. At a P/E of 44.40 and P/B of 7.76, this is a high-risk sugar cycle stock, not a Buffett-style bargain. I also cannot assess leverage because debt/equity is not disclosed, and promoter holding is unavailable. I would need a wide margin of safety, a stabilised sales run-rate, positive ROCE, and clear financial statements before reconsidering. Until then, this is a commodity business selling at a premium price. I would pass.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer